https://www.selleckchem.com/pr....oducts/tecovirimat.h
The mean muscle mass change between CT1 and CT2 was - 2.2 cm /m (range - 10.1 to + 4.8cm /m ). Six-month progression-free survival (PFS) was significantly shorter in patients with at least 10% muscle loss, reaching 50% (95% CI 9.9-9 versus 79.8% (95% CI 62.1-90.6) in others (p = 0.022). The presence of initial sarcopenia was not associated with grade 3-4 toxicity, which was reported in six (46.2%) and seven (46.7%) patients with and without sarcopenia, respectively. Significant and early skeletal muscle loss occurs during treatmen